PL3133396T3 - Sposób leczenia z zastosowaniem leków wychwytujących amoniak - Google Patents

Sposób leczenia z zastosowaniem leków wychwytujących amoniak

Info

Publication number
PL3133396T3
PL3133396T3 PL16176456T PL16176456T PL3133396T3 PL 3133396 T3 PL3133396 T3 PL 3133396T3 PL 16176456 T PL16176456 T PL 16176456T PL 16176456 T PL16176456 T PL 16176456T PL 3133396 T3 PL3133396 T3 PL 3133396T3
Authority
PL
Poland
Prior art keywords
drugs
ammonia
treatment
Prior art date
Application number
PL16176456T
Other languages
English (en)
Inventor
Bruce Scharschmidt
Original Assignee
Horizon Therapeutics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41255339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3133396(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Therapeutics, Llc filed Critical Horizon Therapeutics, Llc
Publication of PL3133396T3 publication Critical patent/PL3133396T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL16176456T 2008-04-29 2009-01-07 Sposób leczenia z zastosowaniem leków wychwytujących amoniak PL3133396T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4883008P 2008-04-29 2008-04-29
US9323408P 2008-08-29 2008-08-29
EP09739263.3A EP2330892B1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs
EP16176456.8A EP3133396B1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs
PCT/US2009/030362 WO2009134460A1 (en) 2008-04-29 2009-01-07 Methods of treatment using ammonia-scavenging drugs

Publications (1)

Publication Number Publication Date
PL3133396T3 true PL3133396T3 (pl) 2019-03-29

Family

ID=41255339

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16176456T PL3133396T3 (pl) 2008-04-29 2009-01-07 Sposób leczenia z zastosowaniem leków wychwytujących amoniak

Country Status (12)

Country Link
US (2) US8642012B2 (pl)
EP (2) EP2330892B1 (pl)
CA (1) CA2735218A1 (pl)
CY (3) CY1118543T1 (pl)
DK (1) DK2330892T3 (pl)
GB (1) GB2470310A (pl)
HU (1) HUS1600057I1 (pl)
LT (1) LTC2330892I2 (pl)
NL (1) NL300854I2 (pl)
NO (1) NO2016023I2 (pl)
PL (1) PL3133396T3 (pl)
WO (1) WO2009134460A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) * 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
JP2017501972A (ja) 2013-11-14 2017-01-19 ウルトラジェニクス ファーマシューティカル インク.Ultragenyx Pharmaceutical Inc. トリグリセリドの固体組成物及びその使用
EP3137116B1 (en) 2014-04-30 2020-12-16 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
EP3180031A1 (en) 2014-08-13 2017-06-21 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN108430514B (zh) 2015-10-29 2023-11-03 约翰霍普金斯大学 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
WO2018170234A1 (en) 2017-03-15 2018-09-20 President And Fellows Of Harvard College Methods and compositions for treating cancer
KR20200018488A (ko) * 2017-05-24 2020-02-19 토리스 게엠베하 고암모니아혈증을 치료하기 위한 글루타민 합성효소의 용도
BR112019028097A2 (pt) 2017-06-28 2020-07-28 Baylor College Of Medicine terapia combinada para tratar distúrbios do ciclo de ureia
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants
JP6797456B2 (ja) 2018-10-04 2020-12-09 アトナープ株式会社 生体情報取得システム、健康管理サーバーおよびシステム
EP3946029A4 (en) 2019-03-28 2022-12-21 Zoll Medical Corporation SYSTEMS AND METHODS FOR PROVIDING DRUG PRESCRIPTION INFORMATION WITH MONITORED CARDIAC INFORMATION
WO2021113662A2 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) * 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
WO1996024571A1 (en) * 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
DE19805854C1 (de) * 1998-02-13 1999-05-12 Claas Usines France Schalteinrichtung für Schneidmesser
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20040229948A1 (en) * 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
GB2465250B (en) 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009134460A1 (en) 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs

Also Published As

Publication number Publication date
GB201013468D0 (en) 2010-09-22
US20100008859A1 (en) 2010-01-14
EP2330892B1 (en) 2016-06-29
DK2330892T3 (en) 2016-08-22
LTC2330892I2 (lt) 2018-06-11
US8642012B2 (en) 2014-02-04
CY1121288T1 (el) 2020-05-29
US20140256807A1 (en) 2014-09-11
EP2330892A1 (en) 2011-06-15
EP2330892A4 (en) 2012-01-11
HUS1600057I1 (hu) 2017-01-30
CY2016053I1 (el) 2017-06-28
NO2016023I1 (no) 2016-12-14
EP3133396B1 (en) 2018-09-05
CA2735218A1 (en) 2009-11-05
NO2016023I2 (no) 2016-12-27
CY2016053I2 (el) 2017-06-28
WO2009134460A1 (en) 2009-11-05
EP3133396A1 (en) 2017-02-22
GB2470310A (en) 2010-11-17
CY1118543T1 (el) 2017-06-28
LTPA2016041I1 (lt) 2017-01-10
NL300854I2 (pl) 2017-02-02

Similar Documents

Publication Publication Date Title
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0910854A2 (pt) métodos de tratamento
IT1391555B1 (it) Apparato trattamento extracorporeo sangue
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
PL3476371T3 (pl) Urządzenie do leczenia gerd
BRPI0910259A2 (pt) métodos de tratamento de inflamação
EP2373163A4 (en) Heterocyclic compounds and methods of use
PL3181134T3 (pl) Bifidobakterie do leczenia cukrzycy i stanów pokrewnych
EP2296593A4 (en) MEDICAL HEAD COVER
BRPI0914294A2 (pt) aparelho de tratamento de cápsulas
DK2330887T3 (da) Behandlingsindretning
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
BRPI0917575A2 (pt) métodos de tratamento de talassemia
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
HUE045367T2 (hu) Kombinált terápia diabétesz kezelésére
EP2253009A4 (en) LOW TEMPERATURE PLASMA PROBE AND METHODS OF USE
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
DK2173831T3 (da) Brøndbehandling
EP3381471C0 (en) PAIN TREATMENT
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
DK3150178T3 (da) Stimuleringsapparat
DK2265296T3 (da) Medicinske apparater med hydrofile belægninger
HRP20181877T1 (hr) Postupci za liječenje lijekovima koji uklanjaju amonijak
EP2393836A4 (en) SAM-6 VARIANTS, TARGET AND METHODS OF USING SAME